Journal articles on the topic 'Bureau Veritas'

The innovative paradigm developed by Bureau Veritas has been applied to achieve superior outcomes and benefits for a major oil and gas player. The focus of this innovative approach achieved operational security and risk management for the critical ageing assets. The paradigm and its vital components will become the benchmark for the management and improvement of the performance of ageing assets and serve as a fundamental input to new generation design for oil and gas facilities. Among the key challenges in managing the performance (risk and integrity) of new and ageing assets are the understanding of process safety and critical equipment condition. When discussing with senior management the issues foremost on their minds, Bureau Veritas has found the answer is a common theme—how can I be confident the design of new or existing facilities is fit-for-purpose for the duration of the asset’s life? The integrated approach has brought together the leading concepts/tools in process risk management and prognostic health and reliability engineering. These components include rigorous risk-assessments of the process as well as sensing design based on failure mode consequence effect analysis (FMCEA), data acquisition and processing (real-time monitoring and data fusion), diagnostic and prognostic models and systems for the effective management asset(s). The result of this approach creates a value proposition of financial significance advantage.

In this paper, Bureau Veritas explains the new international regulations on air pollution, its origin, and its position in the marine market to help and develop several technical solutions suitable to the world’s fleet.

The process of digitalization in our society is undeniable and unstoppable and ships are adapting more and more to this new environment. This offers great advantages, since ships can send/receive all the information on all aspects of their current status (allowing more efficient management during the ship's life and even opening the door to autonomous navigation), but this presents a number of intrinsic difficulties due to their connected state (cybersecurity). All the above will be developed with a massive sensorization of the ships, which will indicate their condition, going from a reactive maintenance to a predictive maintenance. This requires the figure of the digital twin, which digitally represents the physical reality of the ship, and which will be a single source of information for all actors. This digital twin opens the door to "Digital Classification" by Bureau Veritas, in which traditional 2D plans are no longer necessary, but work is done directly in 3D on the Digital Twin. Bureau Veritas, as a reference classification society, has adapted to the current situation of the industry, favoring the digitalization process in all its aspects. The objective of this article is to present the current state and foreseeable evolution of the technology leading to the Digital Twin concept, its implications in the design and maintenance of ships, all from the point of view of a Classification Society while exemplifying the digitalization process of a Classification Society in different aspects.

The article presents generally selected issues regarding the safety of ship structures, fuel containment systems, processing and preparation of LNG liquefied gas as fuel for marine propulsion systems and generating sets, in relation to certain requirements of the IGF Code and the provisions of the classification society Bureau Veritas rules. The publication presents the fundamental criteria and assumptions of the IGF Code, which may be taken into account when creating the concept and design of units powered by LNG fuel, also considering the limits of air pollution emissions from ships defined in Annex VI of the MARPOL Convention.

Introduction: Ultrasound (US) assessment of joints is an evolving point of care tool for the detection of early joint arthropathy (Napolitano M, Kessler CM. Hemophilia A and B. Consultative Hemostasis and Thrombosis, Kitchens, 4th edition); population pharmacokinetic (pop-PK) studies are adopted as a useful instrument to set the prophylaxis regimen for patients with hemophilia, they may improve adherence (Nagao A.et al. Thromb Res. 2019 Jan; 173:79-84) and reduce the annual bleeding rate (ABR). Adherence to continuous intravenous administrations of factor VIII or Factor IX products is challenging, thus patients may experience breakthrough bleedings while on prophylaxis. Repeated US examinations of joint status have recently been advocated to attempt to remedy sub-optimal medication adherence (Di Minno A et al., Blood Rev. 2019 Jan;33:106-116). Aim of the current prospective analysis was to evaluate the impact of combined US assessment and pop-PK study on adherence to treatment and health related quality of life in patients with severe hemophilia A(HA) and B (HB) under regular prophylaxis. Material and methods: This prospective observational study was performed at a single tertiary center from January 2017 to June 2019. Research was conducted following the Helsinki Declaration. All patients included in the study provided a written informed consent for study participation. Patients with severe HA and HB routinely underwent, as part of regular 12-months follow-up visits, the following: US joints evaluation of elbows, knees and ankles using the HEAD-US protocol, treatment adherence evaluation by VERITAS-Pro questionnaire, health -related quality of life assessment by the standardized EQ-5D,EQ-VAS and pop-PK study (WAPPS-Hemo, McMaster University) as needed (i.e.in case of changes in life style, planned treatment switch); each patient visualised US and his estimated PK profile during medial encounters. Compliance to the prescribed treatment was also determined by analysis of patient diaries with infusion logs. Statistical analysis was performed using the SPSS software version 25.0 (SPSS Chicago, IL). Statistical tests were 2-sided, with a significance threshold of 0.05. Results: Twenty consecutive males with severe haemophilia were included in the current analysis, 13 with severe HA, 2 with HA with previous inhibitors and 5 HB, with a median age of 30 (range 14- 56) years and a median ABR of 5 (range:0-12). Nine patients were under primary prophylaxis, 8 under secondary prophylaxis and 3 under tertiary prophylaxis, they all self-infused at home. Four patients had one target joint and 3 patients had multiple target joints. For each enrolled subject, HEAD-US score, VERITAS-pro, EQ5D and EQ-VAS score were assessed at enrolment (T0) and at 12 (T12) and 24 (T24) months follow-up visits, respectively. Pop-PK was assessed in 11 patients: in 7 (5 HA,2 HB) it was assessed twice, before and after treatment switch to extended half-life (EHL) products, in 4 it was assessed once to modify prophylaxis treatment schedules for a more active life-style (N=2) or weight changes (N=2). Median ABR was 4 at T12 and 3.8 at T24. Reported breakthrough bleeds at T12 were 14, mainly trauma-related (N= 8) or affecting target joints (N=4), they were not reported at T24 in patients with PK-driven modified schedules (N=4) and in 4 patients under EHL treatments. Mean HEAD-US score at T0 resulted 8 (range:0-16), at T24 it was 6 (range:0-16). Mean Veritas-Pro score values were 42.7 at TO, 40.1 at T12 and 38.7 at T24. At T0, EQ-5D mean utility score was 0.82 (range: 0.68-1), at T24, the mean was 0.87 (range:0.72-1). In detail, at 24 months follow-up, there was a statistically significant (p<0.05) improvement in adherence to treatment with particular reference to the dimensions of communication and skipped doses. A tendency toward improved HEAD-US score, higher adherence and better quality of life scores, was observed in particular in patients switched to EHL products at T24, at a mean of 10 months after switching (range: 6-22 months). Conclusion: Several combined measures of haemophilia treatment monitoring, allowing visual assessment of joints status and PK profile estimates by patients have here shown to improve treatment adherence and quality of life in patients with HA and HB, this may be not only related to new available treatments but also to an increased awareness and education of patients. Disclosures Napolitano: BIOFVIIIx: Consultancy; Novonordisk: Consultancy, Speakers Bureau; Shire: Other: Expert Testimony, Speakers Bureau; Kedrion: Other: Expert Testimony, Speakers Bureau; Octapharma: Speakers Bureau; Bayer: Consultancy, Other: Expert Testimony. Di Minno:Novo Nordisk: Speakers Bureau; CSL: Speakers Bureau; Sanofi: Speakers Bureau; Bayer: Consultancy, Honoraria, Speakers Bureau; Kedrion: Speakers Bureau; Pfizer: Speakers Bureau.

Currently, as a result of new communications technologies, autonomous ships are even closer to our seas than we could think. But, besides un-doubted advantages, it gives rise to uncertainties and challenges in several aspects, which include those related to the fields of cybersecurity and legislation, in relation to international regulations and national laws. The aspects of autonomous shipping are included in the information regulations of Bureau Veritas, and additional specific tags have been created to collect the cybersecurity/cyberprotection aspects of such ships. The objective of this article is to present the current status and the foreseeable evolution of the regulations on autonomous shipping from the point of view of a Classification Society, as well as the current evolution of the methodologies concerning cybersecurity.

Fixed-duration treatment with venetoclax (Ven), a highly selective Bcl-2 inhibitor combined with an anti-CD20 monoclonal antibody, showed high efficacy inducing high rates of deep responses with undetectable minimal residual disease (uMRD) in patients with previously treated and untreated chronic lymphocytic leukemia (CLL). The efficacy and safety of the Ven and rituximab (VenR) combination have been investigated in a multicenter, prospective study of the GIMEMA group that included young patients with previously untreated CLL (LLC 1518, VERITAS, NCT03455517). The primary endpoint of this study was the CR rate assessed according to the iwCLL criteria. Inclusion criteria were: treatment requirement per iwCLL criteria, age ≤65 years, cumulative Illness rating scale score ≤6, creatinine clearance ≥30 mL/min, and an unfavorable biologic profile with IGHV unmutated and or TP53 disruption. Treatment consisted of the Ven dose ramp-up (from 20 to 400 mg daily, during 5-weeks) followed by Ven 400 mg daily, combined with R for six 28-day courses (375 mg/m2, course 1; 500 mg/m2, courses 2-6). Patients continued with Ven single agent, 400 mg daily, until month 13. Tumor lysis syndrome (TLS) prophylaxis measures included hydration, allopurinol, or rasburicase. All patients received PneumocystisJirovecii prophylaxis. G-CSF was given in patients with recurrent and severe granulocytopenia. Adverse events (AEs) were graded according to the CTCAE criteria v.5, TLS events were classified according to Howard's criteria. Response was assessed at months 7 and 15 and included clinical examination, PB evaluation, BM aspirate, BM biopsy, and CT scan. MRD was checked centrally in the PB and BM by a 6/4-color flow-cytometry assay with a sensitivity of at least 10-4 according to the internationally standardized European Research Initiative on CLL. Quantitative MRD results assessed by flow-cytometry were categorized as uMRD (uMRD4; <10-4), intermediate MRD, or high MRD (≥10-2). MRD was further evaluated by allele-specific oligonucleotide PCR with a sensitivity up to 10-5 in the PB and BM of patients who showed uMRD4 by flow-cytometry. During the follow-up, MRD was monitored every 6 months. Between October 2018 and May 2020, 77 patients with CLL were included in this study. Two patients were off study before the start of treatment (withdrawal of consent, 1; Covid-19 infection, 1) and were not included in the analysis. The median age was 53.5 years (range 38-65). Binet stage B/C was present in 84% of patients, increased beta-2 microglobulin in 41%. Seventy-one (96%) of patients were IGHV unmutated, while 3 (4%) were IGHV mutated and showed TP53 mutation (Table 1). At the data cutoff of June 30, 2020, 65 (87%) patients completed the ramp-up phase. The planned 400 mg dose of Ven was reached within 5 weeks in 78.5% of patients. Response was assessed in 34 patients at the end of the VenR combination therapy. A response was achieved by 32 (94%) patients. Responses included 20 (59%) CRs, 1 CRi (3%) and 11 (32%) PRs due to residual enlarged nodes (median maximum size, 1.9 cm). Treatment failure due to toxicity was recorded in 2 (6%) patients. Overall, a response with uMRD4 by flow-cytometry in the PB was observed in 26 (76.5%) cases, and in the PB and BM, in 17 (50.0%). The rates of patients with CR and uMRD4 by flow-cytometry in the PB, and both in the PB and BM, were 44%, and 35%, respectively (Table 2). No detectable disease by PCR, both in the PB and BM, was observed in 4 (12%) patients. With a median follow-up of 4.5 months from the start of therapy, no patient has progressed or died. Fifty-three percent of patients were hospitalized during the first seven days of the Ven ramp-up phase. A transient laboratory TLS was observed in 3 patients. Treatment was discontinued after the first dose of Ven in 1 patient with evidence of laboratory TLS associated with severe neurologic toxicity due to the concomitant administration of fentanyl. Selected grade ≥3 AEs included neutropenia in 10 patients (ramp-up phase, 5) and neutropenic fever in 4. Grade ≥3 infection was recorded in 3 patients and was the reason for treatment discontinuation in 1 who developed COVID-19 pneumonia. In conclusion, the preliminary results of this study demonstrate the high efficacy of the front-line VenR combination, which resulted in a high proportion of CRs and responses with uMRD4 in young patients with CLL and an unfavorable biologic profile. Disclosures Mauro: Astrazeneca: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jannsen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Octopharma: Consultancy. Reda:Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Trentin:Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Shire: Honoraria; Takeda: Membership on an entity's Board of Directors or advisory committees; Octapharma: Membership on an entity's Board of Directors or advisory committees. Coscia:Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm Therapeutics: Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Sportoletti:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Laurenti:Roche: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Gaidano:Astrazeneca: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sunesys: Membership on an entity's Board of Directors or advisory committees. Marasca:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Honoraria; Roche: Membership on an entity's Board of Directors or advisory committees. Murru:Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Rigolin:Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Scarfo:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees. Marchetti:Pfizer: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees. Levato:Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Galieni:Celgene: Honoraria; Takeda: Honoraria; AbbVie: Honoraria; Janssen: Honoraria. Liberati:Verastem: Research Funding; Onconova: Research Funding; Janssen: Honoraria, Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Honoraria, Research Funding; Pfizer: Research Funding; Karyopharm: Research Funding; Morphosys: Research Funding; Novartis: Research Funding; GSK: Research Funding; Incyte: Honoraria; Oncopeptides: Research Funding; Takeda: Research Funding. Molica:Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Visentin:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Vitale:Janssen: Honoraria. Del Giudice:Janssen: Other: grant for meeting participation; Tolero: Membership on an entity's Board of Directors or advisory committees; Roche: Other: grant for meeting partecipation; AstraZeneca: Membership on an entity's Board of Directors or advisory committees. Cuneo:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astra Zeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Foà:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees.

El comportamiento fraudulento en el consumo de agua potable es un problema importante que enfrentan las empresas de tratamiento de agua debido a que genera pérdidas económicas significativas. Caracterizar consumos fraudulentos es una tarea compleja, basada principalmente en la experiencia, y que presenta el desafío de la incorporación constante de nuevos clientes y la variación en el consumo mensual. En esta investigación, las técnicas de minería de datos se utilizan para caracterizar y predecir los consumos fraudulentos de agua potable. Para esto, se utilizó información histórica relacionada con el consumo. Las técnicas aplicadas mostraron un alto rendimiento predictivo y su aplicación permitirá enfocar eficientemente los recursos orientados a evitar este tipo de fraude. Palabras Clave: minería de datos, machine learning, agua potable, detección de fraude. Referencias [1]Centro de Investigación Periodística., «Producción y facturación de agua potable,» 30 Julio 2020. [En línea]. Disponible en: https://ciperchile.cl/wp-content/uploads/gestion-siis-2014-pag 88.pdf. [Último acceso: 30 Julio 2020]. [2]Bureau Veritas S.A., «https://www.bureauveritas.cl/es,» [En línea]. Disponible en: https://www.bureauveritas.cl/es/bureau-veritas-lider-mundial-en-ensayos-inspeccion-y-certificacion. [Último acceso: 1 Junio 2020]. [3]Essbio S.A., «www.essbio.cl,» [En línea]. [4]I. Monedero, F. Biscarri, J. Guerrero, M. Peña, M. Roldán y C. León, «Detection of water meter under-registration using statistical algorithms,» Journal of Water Resources Planning and Management, vol. 142, nº 1, p. 04015036, 2016. [5]I. Monedero, F. Biscarri, C. León, J. Guerrero, J. Biscarri y R. Millán, «Detection of frauds and other non-technical losses in a power utility using Pearson coefficient, Bayesian networks and decision trees,» International Journal of Electrical Power & Energy Systems, vol. 34, nº 1, pp. 90-98, 2012. [6]S. Wang, «A comprehensive survey of data mining-based accounting-fraud detection research,» de 2010 International Conference on Intelligent Computation Technology and Automation, New York, 2010. [7]J. Bierstaker, R. Brody y C. Pacini, «Accountants' perceptions regarding fraud detection and prevention methods,» Managerial Auditing Journal, vol. 21, nº 5, pp. 520-535, 2006. [8]C. Phua, V. Lee, K. Smith y R. Gayler, «A comprehensive survey of data mining-based fraud detection research,» arXiv preprint arXiv:1009.6119, 2010. [9]S. Kotsiantis, I. Zaharakis y P. Pintelas, «Machine learning: a review of classification and combining techniques,» Artificial Intelligence Review, vol. 26, nº 3, pp. 159-190, 2006. [10]J. Han, J. Pei y M. Kamber, Data Mining: Concepts and Techniques, Elsevier, 2011.

В статті досліджується задача напружено-деформованого стану і оцінки міцності порожнистої замкненої тороїдальної оболонки, яка виконана з полімерного композиційного матеріалу способом намотування. Удосконалено метод розрахунку напружено-деформованого стану і оцінки міцності при гідростатичному стисканні міцного корпусу підводного апарату тороїдальної форми з урахуванням конструктивно-технологічних факторів виготовлення способом намотування волокном (стрічкою) із полімерних композиційних матеріалі та рекомендацій класифікаційного товариства Bureau Veritas, щодо оцінки пружних характеристик композиційного матеріалу по властивостям його компонентів. Отримано закономірності впливу на напружено-деформований стан намотаного тороїдального міцного корпусу схем армування, геометричних параметрів корпусу, перспективних типів армуючих наповнювачів та сполучників, змінної товщини та її осереднення. Встановлено, що не врахування конструктивно-технологічних факторів виготовлення способом намотування та особливостей розрахунку композиційних матеріалів і використання спрощених методів розрахунку призводить до зменшення напружень в два рази та виникненню помилки в небезпечну сторону. Обмеження по міцності прийняті у вигляді комбінованого критерія Цая-Ву-Гофмана. Проведено оцінку техніко-економічної ефективності використання високоміцних волокнистих матеріалів для тороїдальних міцних корпусів при обмеженні по міцності з метою створення раціональних в ваговому та технологічному відношенні корпусів в залежності від глибини експлуатації на початковій стадії проектування апаратів. Встановлено, що для міцних кор-пусів підводних апаратів тороїдальної форми найбільше підходять епоксипластики на основі середніх по модулю та високоміцних вуглецевих волокон.

Experiments and theoretical analyses of sandwich materials which are used in the design of a solar-powered boat are required to fully complete the analysis of the hull strength. Rule analysis of global hull girder loads or panel under global loads (laminate buckling, maximum stress in each layer, and combined stress) will be used to determine the hull strength of the boat. In this research, the mechanical properties of facing laminate and sandwich material of VARTM-Vacuum Infusion are investigated. Moreover, the analysis from the result of the experiment and the theoretical calculation will be used as a reference to perform the hull strength calculations. From the experiment, an average tensile modulus of 15.21 GPa is obtained with a standard deviation of ± 1 GPa and the theoretical analyses calculation for the tensile modulus value is 54.990 5 GPa. Furthermore, an average flexural modulus value is 21 261.8 N mm-2 with a standard deviation of ± 2 301.17 N mm-2 and a theoretical analyses calculation for the flexural modulus value is 26 833.5 N mm-2. In the end, the calculation from the experimental and theoretical analysis may be applicable to calculate the hull strength of the vessel. In conclusion, the calculation of the hull strength of the solar-powered boat using the Bureau Veritas (BV) classification rules has met the required standards.

Santos, Beach Energy and Senex Energy are collaborating with the SA Government and TAFE SA to set up a hub for onshore oil and gas training in Adelaide. The training facility provides a fully immersive simulated oil and gas production environment, as well as static equipment displays for demonstration and educational purposes. It is used for technical training, including safety, environmental and sustainable operational principles and key maintenance activities. The simulated production environment includes different pump types, gas compressors, a pig launcher and receiver, gas metering skid, field separator and small tanks, as well as associated pressure safety valves, flow valves and other instruments. Water is used to simulate oil and air is used to simulate gas flow. The static equipment display includes various valve types, flanges and a wellhead. Santos, as operator of the SA Cooper Basin joint venture (of which Beach Energy is a member), has committed significant oil and gas production and mechanical equipment, engineering design, transportation and installation of the training facility’s equipment. The SA Government, Senex Energy and Beach Energy have committed funding for fit-out, capital works and the running of the facility for the first two years. Industry partners GPA Engineering, Fyfe Engineering, Logicamms, Veolia Environmental Services, Toll Energy, Transfield Services, Ottoway Engineering, Bureau Veritas, MRC Group, Max Cranes, Whitham Media Australia, Inductabend, Toyota Australia, James Walker Australia, Coventry Fasteners, Centralian Controls and Central Diesel are providing expertise and services. The training facility officially opened on 16 February 2015

Introduction: It is anticipated that many patients with hemophilia are likely to switch from one coagulation factor product to a newer agent within the next few years. New replacement factor formulations have been developed using several approaches that have theoretical benefit. However, except for pharmacokinetic properties, it may be difficult to determine whether they are superior to current clinically successful preparations. Rurioctocog alfa pegol (Adynovate®), a pegylated, extended half-life factor VIII (FVIII) concentrate, received United States Food and Drug Administration approval in 2015. Its efficacy and safety for the treatment of hemophilia A have been demonstrated in multiple studies (Konkle et al. 2015; Gruppo et al. 2019; Mullins et al. 2017). The ATHN 2: Factor Switching Study provided the opportunity to longitudinally observe previously treated hemophilia patients switching to rurioctocog alfa pegol to identify dosing regimens, patient satisfaction with the change in therapy, impact on health states and productivity. Methods: The ATHN 2: Factor Switching Study is sponsored by the American Thrombosis and Hemostasis Network (ATHN) and is being conducted at ATHN-affiliated sites in the US. This multi-center, longitudinal, observational study enrolled male and female children and adults with moderate or severe congenital hemophilia A or B (factor VIII or IX clotting activity ≤5% of normal) who were previously treated with plasma-derived or recombinant factor replacement products with ³50 exposure days. Patients receiving care from one of 30 hemophilia treatment centers were enrolled into 2 arms: 1) a prospective arm including those switching factor replacement products who were followed for <1 year; and 2) a retrospective arm including those who had switched factor replacement products within the past 50 weeks at the time of enrollment. Patients were assessed retrospectively or followed prospectively for <1 year. Treatment administered in ATHN 2 was at the discretion of the patient's provider. Each patient was seen during a study visit or contacted by telephone at least once every 3 months. A product-specific module developed for rurioctocog alfa pegol included assessment of dosing and treatment satisfaction vs prior therapy; adherence to therapy assessed using Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-Pro), a validated instrument with 6 subscales (timing, dosing, planning, remembering, skipping, communication); health states measured by the EQ-5D-DL; work productivity assessed by the Work Productivity Activity Impairment Questionnaire (WPAI); and overall satisfaction with therapy. Results: Patients (n=59) with hemophilia A were enrolled into the rurioctocog alfa pegol sub-study by May 1, 2020. Mean (± standard deviation [SD]) age was 25 ± 18 years (range = 4-77 years); 72.9% (n=43) were in the prospective arm and 27.1% (n=16) in the retrospective arm; 11.9% (n=7) had moderate hemophilia A and 88.1% (n=52) had severe disease. All were taking rurioctocog alfa pegol as prophylaxis. At study end, results for dosing (Table 1) indicated the most common treatment regimen was twice weekly (45.1%, n=23), and mean nominal dose was 50 ± 10 U/kg. Patients were highly adherent to prophylaxis with rurioctocog alfa pegol with a mean total VERITAS-Pro score of 31.4 ± 8.4; adherence improved slightly over time (32.6 ± 9.0 at baseline vs 29.2 ± 4.2 at month 12). Patients strongly preferred rurioctocog alfa pegol vs all prior factor products for controlling bleeding, convenience, finding time to take and ease of administering FVIII, and how often they were required to take factor (Table 1). Overall, 76.5% of patients were very satisfied or satisfied with rurioctocog alfa pegol. Assessment of health states indicated that patients generally had no or slight problems with mobility, activities, or self-care; and were not in pain or anxious/depressed. Patients generally missed no time from work or school. Overall health was self-rated at 89.0 ± 13.0 on a scale from 0 (worst health) to 100 (best health) and remained stable from baseline (88.0 ± 14.0) to month 12 (87.8 ± 15.3). Conclusions: Moderate and severe hemophilia A patients enrolled in ATHN 2 who received rurioctocog alfa pegol for prophylaxis enjoyed excellent health, had little to no school or work impairment and were adherent to, and satisfied with, their treatment regimen. Disclosures Recht: Spark: Research Funding; CSL Behring: Consultancy, Other: personal fees; Novo Nordisk: Consultancy, Other: personal fees, Research Funding; Genentech: Consultancy, Other: personal fees, Research Funding; Pfizer: Consultancy, Other: personal fees; BioMarin: Research Funding; Takeda: Consultancy, Other: personal fees, Research Funding; uniQure: Consultancy, Other: personal fees, Research Funding. Guelcher:Novo-Nordisk: Consultancy; Octapharma: Consultancy; Genentech, Octapharma, CSL Behring, Takeda, Pfizer, Novo Nordisk: Consultancy; Takeda: Consultancy. Neufeld:Bayer: Other: DSMB; genetech: Consultancy; Novo Nordsik: Consultancy; Octapharma: Consultancy; Takeda: Consultancy; Imara Pharma: Other: DSMB service; ApoPharma/Chiezi: Other: DSMB service; Pfizer: Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy; Acceleron Pharma: Consultancy, Other: DSMB. Ragni:Alnylam/Sanofi, ATHN, BioMarin, Bioverativ, Sangamo, Spark: Research Funding; Alnylam/Sanofi, BioMarin, Bioverativ, Spark: Consultancy; BioMarin: Consultancy, Research Funding; Bioverativ: Consultancy, Research Funding; Spark: Consultancy, Research Funding; Takeda: Research Funding; Sangamo: Consultancy, Research Funding; Alnylam Pharmaceuticals Inc., Baxalta/Takeda, BioMarin, Bioverativ, and Spark Therapeutics: Membership on an entity's Board of Directors or advisory committees; American Thrombosis Hemostasis Network: Other: Committee work; Baxalta/Takeda, CSL Behring, Genentech, a member of the Roche Group, OPKO Biologics, and Vascular Medicine Institute: Research Funding. Sidonio:Biomarin: Consultancy, Honoraria, Speakers Bureau; Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau; Grifols: Research Funding; Spark: Consultancy, Honoraria; Uniqure: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Novo Nordisk: Consultancy, Honoraria; Octapharma: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria; Genentech: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Bayer: Consultancy, Honoraria. Takemoto:Novartis: Other: DMBC; Genentech: Consultancy. Tarantino:Spark: Membership on an entity's Board of Directors or advisory committees; CDC: Membership on an entity's Board of Directors or advisory committees; Dova: Membership on an entity's Board of Directors or advisory committees; Biomarin: Membership on an entity's Board of Directors or advisory committees; NovoNordisk: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Research Funding; Octapharma: Membership on an entity's Board of Directors or advisory committees; Grifols: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genentech: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; HRSA: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other; Sobi: Membership on an entity's Board of Directors or advisory committees. Caicedo:Takeda: Current Employment. Denne:Takeda: Current Employment.

El presente trabajo de investigación ha servido para determinar la capacidad de remoción de metales pesados y encontrar el vegetal adecuado, aprovechando las bondades de las siguientes especies: Eichhornia crassipes (Jacinto de agua, flor de boca o camalote), Schoenoplectus colifornicus (Junco o totora), y Phragmites australis (Carricillo o gramínea trepadora), para ello se construyeron tres estanques de madera debidamente impermeabilizados de las siguientes dimensiones: 0.30 metros de ancho x 0.40 metros de alto y 1.60 metros de largo, haciendo un volumen de 0.192 metros cúbicos, ubicada próximo a una vivienda en el centro poblado de Nueva Esperanza en el distrito de Santa María provincia de Huaura, región Lima. En cada estanque se sembraron las tres variedades de plantas y a cada una de ellas ha ingresado agua residual de la vivienda, de manera ininterrumpida y luego de más de 90 días de su crecimiento se contrataron los servicios de un laboratorio acreditado Bureau Veritas para realizar los análisis respectivos. Dichos resultados indican que los tres tipos de vegetales asimilan los metales elegidos, siendo el más eficiente el Eichhornia Crassipes (Jacinto de agua), con 94.73 % para el Niquel, 84.36 % para el Plomo, y 78.48 % para el cadmio, en el caso del Schoenoplectus Colifornicus (Junco), para el Niquel resultó 83.00 %, Plomo 61.23 % y Cadmio 51.90 %, y para el Phragmites Australis (carricillo), en el caso del Niquel fue 79.90 %, Plomo 60.23 % y Cadmio 29.11 %, por lo tanto se recomienda el Jacinto de agua para captar metales pesados de aguas residuales domésticas y/o industriales. Mientras que en el cuadro de análisis respecto a los tres tipos de vegetales, en el primer caso el resultado de los tres tipos de vegetales que crecen en forma silvestre en los pantanos cercanos a la zona, formando grandes comunidades, mientras que el segundo análisis corresponde a los tres tipos de vegetales que han sido sembrados en los estanque en los cuales ingresa agua residual domestica de una vivienda, precisamente para notar las diferencias en cuanto al contenido de metales pesados, siendo los resultados los siguientes: 57.00 % para el Jacinto de agua, 42.00 % para el junco y 37.00 % para el carricillo, con ello se demuestra que de los tres tipos de vegetales estudiados el Jacinto de agua es el más eficiente, por lo tanto es recomendable para captación de metales pesados de las aguas residuales domésticas.

Underwater acoustic signature identification has been employed as a technique for detecting underwater vehicles, such as in anti-submarine warfare or harbour security systems. The underwater sound channel, however, has interference due to spatial variations in topography or sea state conditions and temporal variations in water column properties, which cause multipath and scattering in acoustic propagation. Thus, acoustic data quality control can be very challenging. One of challenges for an identification system is how to recognise the same target signature from measurements under different temporal and spatial settings. This paper deals with the above challenges by establishing an identification system composed of feature extraction, classification algorithms, and feature selection with two approaches to recognise the target signature of underwater radiated noise from a research vessel, Ocean Researcher III, with a bottom mounted hydrophone in five cruises in 2016 and 2017. The fundamental frequency and its power spectral density are known as significant features for classification. In feature extraction, we extract the features before deciding which is more significant from the two aforementioned features. The first approach utilises Polynomial Regression (PR) classifiers and feature selection by Taguchi method and analysis of variance under a different combination of factors and levels. The second approach utilises Radial Basis Function Neural Network (RBFNN) selecting the optimised parameters of classifier via genetic algorithm. The real-time classifier of PR model is robust and superior to the RBFNN model in this paper. This suggests that the Automatic Identification System for Vehicles using Acoustic Signature developed here can be carried out by utilising harmonic frequency features extracted from unmasking the frequency bandwidth for ship noises and proves that feature extraction is appropriate for our targets. References Nathan D Merchant, Kurt M Fristrup, Mark P Johnson, Peter L Tyack, Matthew J Witt, Philippe Blondel, and Susan E Parks. Measuring acoustic habitats. Methods in Ecology and Evolution, 6(3):257265, 2015. doi:10.1111/2041-210X.12330. Nathan D Merchant, Philippe Blondel, D Tom Dakin, and John Dorocicz. Averaging underwater noise levels for environmental assessment of shipping. The Journal of the Acoustical Society of America, 132(4):EL343EL349, 2012. doi:10.1121/1.4754429. Chi-Fang Chen, Hsiang-Chih Chan, Ray-I Chang, Tswen-Yung Tang, Sen Jan, Chau-Chang Wang, Ruey-Chang Wei, Yiing-Jang Yang, Lien-Siang Chou, Tzay-Chyn Shin, et al. Data demonstrations on physical oceanography and underwater acoustics from the marine cable hosted observatory (macho). In OCEANS, 2012-Yeosu, pages 16. IEEE, 2012. doi:10.1109/OCEANS-Yeosu.2012.6263639. Sauda Sadaf P Yashaswini, Soumya Halagur, Fazil Khan, and Shanta Rangaswamy. A literature survey on ambient noise analysis for underwater acoustic signals. International Journal of Computer Engineering and Sciences, 1(7):19, 2015. doi:10.26472/ijces.v1i7.37. Shuguang Wang and Xiangyang Zeng. Robust underwater noise targets classification using auditory inspired time-frequency analysis. Applied Acoustics, 78:6876, 2014. doi:10.1016/j.apacoust.2013.11.003. LG Weiss and TL Dixon. Wavelet-based denoising of underwater acoustic signals. The Journal of the Acoustical Society of America, 101(1):377383, 1997. doi:10.1121/1.417983. Timothy Alexis Bodisco, Jason D'Netto, Neil Kelson, Jasmine Banks, Ross Hayward, and Tony Parker. Characterising an ecg signal using statistical modelling: a feasibility study. ANZIAM Journal, 55:3246, 2014. doi:10.21914/anziamj.v55i0.7818. José Ribeiro-Fonseca and Luís Correia. Identification of underwater acoustic noise. In OCEANS'94.'Oceans Engineering for Today's Technology and Tomorrow's Preservation.'Proceedings, volume 2, pages II/597II/602 vol. 2. IEEE. Linus YS Chiu and Hwei-Ruy Chen. Estimation and reduction of effects of sea surface reflection on underwater vertical channel. In Underwater Technology Symposium (UT), 2013 IEEE International, pages 18. IEEE, 2013. doi:10.1109/UT.2013.6519874. G.M. Wenz. Acoustic ambient noise in the ocean: spectra and sources. Thesis, 1962. doi:10.1121/1.1909155. Donald Ross. Mechanics of underwater noise. Elsevier, 2013. doi:10.1121/1.398685. Chris Drummond and Robert C Holte. Exploiting the cost (in) sensitivity of decision tree splitting criteria. In ICML, volume 1, 2000. Charles Elkan. The foundations of cost-sensitive learning. In International joint conference on artificial intelligence, volume 17, pages 973978. Lawrence Erlbaum Associates Ltd, 2001. Chris Gillard, Alexei Kouzoubov, Simon Lourey, Alice von Trojan, Binh Nguyen, Shane Wood, and Jimmy Wang. Automatic classification of active sonar echoes for improved target identification. Douglas C Montgomery. Design and analysis of experiments. John wiley and sons, 2017. doi:10.1002/9781118147634. G Taguchi. Off-line and on-line quality control systems. In Proceedings of International Conference on Quality Control, 1978. Sheng-Ju Wu, Sheau-Wen Shiah, and Wei-Lung Yu. Parametric analysis of proton exchange membrane fuel cell performance by using the taguchi method and a neural network. Renewable Energy, 34(1):135144, 2009. doi:10.1016/j.renene.2008.03.006. Genichi Taguchi. Introduction to quality engineering: designing quality into products and processes. Technical report, 1986. doi:10.1002/qre.4680040216. Richard Horvath, Gyula Matyasi, and Agota Dregelyi-Kiss. Optimization of machining parameters for fine turning operations based on the response surface method. ANZIAM Journal, 55:250265, 2014. doi:10.21914/anziamj.v55i0.7865. Chuan-Tien Li, Sheng-Ju Wu, and Wei-Lung Yu. Parameter design on the multi-objectives of pem fuel cell stack using an adaptive neuro-fuzzy inference system and genetic algorithms. International Journal of Hydrogen Energy, 39(9):45024515, 2014. doi:10.1016/j.ijhydene.2014.01.034. Antoine Guisan, Thomas C Edwards Jr, and Trevor Hastie. Generalized linear and generalized additive models in studies of species distributions: setting the scene. Ecological modelling, 157(2-3):89100, 2002. doi:10.1016/S0304-3800(02)00204-1. Sheng Chen, Colin FN Cowan, and Peter M Grant. Orthogonal least squares learning algorithm for radial basis function networks. IEEE Transactions on neural networks, 2(2):302309, 1991. doi:10.1109/72.80341. Howard Demuth and Mark Beale. Neural network toolbox for use with matlab-user's guide verion 4.0. 1993. Janice Gaffney, Charles Pearce, and David Green. Binary versus real coding for genetic algorithms: A false dichotomy? ANZIAM Journal, 51:347359, 2010. doi:10.21914/anziamj.v51i0.2776. Daniel May and Muttucumaru Sivakumar. Techniques for predicting total phosphorus in urban stormwater runoff at unmonitored catchments. ANZIAM Journal, 45:296309, 2004. doi:10.21914/anziamj.v45i0.889. Chang-Xue Jack Feng, Zhi-Guang Yu, and Andrew Kusiak. Selection and validation of predictive regression and neural network models based on designed experiments. IIE Transactions, 38(1):1323, 2006. doi:10.1080/07408170500346378. Yin-Ying Fang, Ping-Jung Sung, Kai-An Cheng, Meng Fan Tsai, and Chifang Chen. Underwater radiated noise measurement of ocean researcher 3. In The 29th Taiwan Society of Naval Architects and Marine Engineers Conference, 2017. Yin-Ying Fang, Chi-Fang Chen, and Sheng-Ju Wu. Analysis of vibration and underwater radiated noise of ocean researcher 3. In The 30th Taiwan Society of Naval Architects and Marine Engineers Conference, 2018. Det Norske Veritas. Rules for classification of ships new buildings special equipment and systems additional class part 6 chapter 24 silent class notation. Rules for Classification of ShipsNewbuildings, 2010. Underwater acousticsquantities and procedures for description and measurement of underwater sound from ships-part 1requirements for precision measurements in deep water used for comparison purposes. (ISO 17208-1:2012), 2012. Bureau Veritas. Underwater radiated noise, rule note nr 614 dt r00 e. Bureau Veritas, 2014. R.J. Urick. Principles of underwater sound, volume 3. McGraw-Hill New York, 1983. Lars Burgstahler and Martin Neubauer. New modifications of the exponential moving average algorithm for bandwidth estimation. In Proc. of the 15th ITC Specialist Seminar, 2002. Bishnu Prasad Lamichhane. Removing a mixture of gaussian and impulsive noise using the total variation functional and split bregman iterative method. ANZIAM Journal, 56:5267, 2015. doi:10.21914/anziamj.v56i0.9316. Chao-Ton Su. Quality engineering: off-line methods and applications. CRC press, 2016. Jiju Antony and Mike Kaye. Experimental quality: a strategic approach to achieve and improve quality. Springer Science and Business Media, 2012. Ozkan Kucuk, Tayeb Elfarah, Serkan Islak, and Cihan Ozorak. Optimization by using taguchi method of the production of magnesium-matrix carbide reinforced composites by powder metallurgy method. Metals, 7(9):352, 2017. doi:10.3390/met7090352. G Taguchi. System of experimental design, quality resources. New York, 108, 1987. Gavin C Cawley and Nicola LC Talbot. Efficient leave-one-out cross-validation of kernel fisher discriminant classifiers. Pattern Recognition, 36(11):25852592, 2003. doi:10.1016/S0031-3203(03)00136-5.

River sea vessels are ships for inland navigation and suitable for restricted navigation at sea in regions where, -significant wave height does not exceed 2m, according to Bureau Veritas Rules for the classification of inland vessels. In a container vessel structure, almost the entire deck space is occupied by hatches, leaving a narrow strip of deck plating outboard. This calls for a topside structure of heavy plating or a double hull to provide material in tension, stiffness against lateral and torsional loads, and resistance to buckling in compression when the vessel is in sagging condition. For sea going open deck vessels, torsional loading plays a predominant part to the hull girder strength and for inland navigation open deck vessels; the effect of torsion is rather negligible. Keeping this scenario in mind, the aim of this project is to investigate the hull strength of a river sea container vessel under combined bending and torsional loading to study the effect of torsion on river sea open deck vessel. To perform the strength analysis, firstly, a finite element model is created using Femap with NX Nastran software for the investigated vessel. Therefore, still water and wave loads are calculated using direct calculation. To find out the still water loads Argos software is used and for the wave induced loads potential flow software Hydrostar is used. Next, Finite element model is verified with classical beam theory and thin wall girder theory. Then the effect of various loading conditions on structural response is investigated. After, structural response of different hull configurations are scrutinized under combined bending and torsional loading. Finally, some recommendations are proposed for structural response of river sea container vessel subjected to combined bending and torsional loading.